Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Must have missed Dr Berend's presentation at the Modern Musculoskeletal Care Symposium
<<<<<<< No doctor is going to advocate using this device FOR ANYTHING >>>>>>>
Dr Berend, Chief Medical Officer at the Ortho Alliance, is advocating for the use of RecoveryRx at all of the 11 Ortho Alliance Orthopedic Surgery Centers. Those 11 Surgery Centers are staffed by 200 doctors doing thousands of surgeries each year.
You are not excited about a rise in BIEL's SP because you want BIEL to fail and post here repeatedly to further that goal. Many times you have posted inaccurate information in order to falsely discredit BIEL. Who can forget your insistence that the 'ActiPatch 30 Day Money Back Guarantee' offer was a scam.
<<<<<<<<<< Nobody would believe a stockholder is excited about a price move of .0001 >>>>>>>>>
I want BIEL to succeed, so a move from 2 to 3 is significant for me and other BIEL Longs. You don't get to 3 until the Ask selling at 2 has ended and you don't get to 4 until the Ask selling at 3 has ended, etcetera, etcetera.
Responding to your bashing buddy chsmoke who was hyping $280 worth of shares Sold at 2.
Zero Trades with .0001 on the Bid Price today, remember how important you felt that stat was over the last couple of weeks, pumping it over and over.
Shocking, Buys @ 3 = 3.3 million shares, Sells @ 2 = 1.4 million shares
When will Staelin announce a new BIEL partner?
When will Staelin announce RecoveryRx ES news?
When will Staelin announce RecoveryRx use in all of the Ortho Alliance Orthopedic Surgery Clinics?
When will Staelin announce the replenishment order for Adcock Ingram?
50 million shares Traded at 2, 794k shares Traded at 1, just sayin!!!
Now 2 Bid with 47 million share Size vs 3 Ask .
Big change in wind direction, 40 million shares at 2 moves BIEL to a 2 Bid, 3 Ask
11:15 sees 40 million shares @ 2 Traded.
The 2 Ask that was stuck at a 2.5 million share Size turns into a 2 Bid with a 47 million share Size.
BIEL's Number One Purveyor of BS
<<<<<<<<< Why do you bother, spending so much time on this? >>>>>>>>>
My last post prior to today was on 2/16, 3 days with no BIEL posts.
During that same 3 day period you posted 15 times. Your posts are all promoting the destruction of BIEL which says a lot about who you are. 14 years of negative energy focused on destroying something, and failing each of those 14 years. What a Waste of a Life.
You missed a few significant quotes
"The Company, working with its Chinese manufacturer, recently redesigned the manufacturing process to increase the reliability and shelf life of its current OTC product. The Company also did a proof-of-concept production run of its newly designed RecoveryRx product that is 50% more powerful and has a larger antenna thereby increasing the size of the surgical incision that can be treated. The plan is to test market these devices in the near future. (would a company with little cash invest in a redesign of its product if they did not anticipate demand for that product?)
"The Company is continuing talks with major distributors, both internationally and domestically. These talks are in different stages of progress, from discussing final approval and registration, to initial exploration of possible interest. Given the unique advantages of our product offerings, these discussions often take a long time, especially with major distributors that have multiple levels of management review." (This is a big improvement from the 12/25/23 Distribution Update which talked about KT forfeiting their exclusive US rights due to new management not actively promoting the KT Wave)
"Company representatives attended the Modern Musculoskeletal Care Symposium this past weekend in Columbus, Ohio. We were once again invited to exhibit and Dr. Berend spoke to the medical professionals in attendance about “Non Thermal Pulsed Shortwave Therapy for Pre and Post Op Pain” Our attendance at the show was predicated on the expectation that the use of RecoveryRx will expand through the OrthoAlliance (https://orthoalliance.com/) organization in the next few months." (Dr Berend is the Chief Medical Officer for the Ortho Alliance which has 180 doctors involved in orthopedic surgery)
"The Company is exploring entering into legal action against Mundi Pharma South East Asia for breach of contract. They signed a five-year contract in October of 2018 with BioElectronics Corporation, agreeing to purchase a minimum of approximately $14,000,000 worth of product from us over the next five years of the contract. However, they never completed the registration of the products into the five territories that we granted them exclusive distributorship and only took ownership of a small amount of the inventory. We have engaged both local counsel and counsel in Singapore, where any arbitration action would need to take place. The Company is actively seeking financial backing to support this legal action." (Mundi Pharma violated the terms of their contract with BIEL costing BIEL millions of dollars in revenue, BIEL is attempting to get compensation for this breach of contract via the courts)
MM now stands for Market Manipulators, 16.1 million shares shorted on a 17.3 million share day, only 1.2 million shares were sold by the actual owners of their shares today, Sells = 100,100 shares , Buys = 17.2 million shares.
AH form T trade of 15.3 million shares @ 2, MMs moved the Ask Price to 3 before the AH trade so it would record as a Neutral Trade.
FINRA daily Reg SHO Short Report
Date .... Symbol .. Short vol ... Total Vol
20240216 | BIEL | 16145000 ||17316011
https://www.finra.org/finra-data/browse-catalog/short-sale-volume-data/daily-short-sale-volume-files (go to the 'ORF' section of the report)
What a moronic post, the Opioid Challange was an FDA program, initiated due to the Opioid Epidemic, to develop and promote products that would reduce the need for Opioid use.
Over 250 companies, BIEL was one of them, submitted proposals to receive FDA assistance per the Challenge.
The FDA chose 8 companies to assist. Their products included, Transcranial Magnetic Stimulation, Smart Pill Bottles, Overdose Detection Device, Virtual Reality Treatments.
BIEL's submission was not selected along with 241+ other companies that were not selected.
Regarding the "Lying" statement, it is interesting that the poster who lies every time they post a 'Sales Track' statistic, since 'Sales Track' does not exist, would want to bring up the subject of "Lying".
You are aware that the MMs set the Bid and Ask prices, right
Today they shorted another 52 million shares to hold the Ask at .0002, that is in addition to yesterday's 62 million shares shorted to do the same.
The 2 Ask Size averaged 2.5 million shares all day and with that 2.5 million shares the MMs filled 94 million shares of 2 Buying. My favorite is the final trade of the day, a Buy at 2 for 44,269,500 shares filled with 2.8 million shares on the 2 Ask Size. Anyone with access to Time/Sales data can see the manipulation for themselves.
Date .... Symbol .. Short vol ... Total vol
20240215 | BIEL | 51996999 ||122937104
20240214 | BIEL | 62166622 ||138545854
Dr Staelin is an Officer of BIEL, Chairman of the Board, he is liable for false statements about BIEL
You are an anonyms message board poster with a long history of bashing BIEL.
Significant adjustment in outlook compared to the December Update
2/15/2024 COB Update, condensed version, Red notes are my opinion
Clinicals in Progress
Surgical Analgesia - UCSD 120 patients, estimated end date 3/20/2024, "primary outcome measures being pain levels and opioid consumption measured", "the study will be able to assess the efficacy of our model 088 in not only reducing the acute surgical pain and opioid use". (sounds like this study would meet the 'No Pain Act' requirement for proof of reducing opioid consumption)
Thumb Arthritis - Stanford 60 patients, standard device was modified for thumb use, estimated completion April/may 2024 (hard to find a more respected name in medical research than Stanford)
Clinicals in peer Review
Post-Amputation Pain - UCSD, under review for 'Regional Anesthesia and Pain Journal', presentation will occur at their March conference ( UCSD's Dr Illfeld is a well respected researcher with over 100 published papers, medical professionals take notice of this work)
Canine Osteoarthritis - Showed 96% significant improvement, under review for 'Veterinarian Medicine and Science Journal', packaging for a Veterinarian product has been ordered (BIEL being proactive to capitalize on this publication)
Manufacturing
Redesign of the manufacturing process for increased reliability and shelf life, proof of concept production run of the RecoveryRx ES has been done, test marketing in near future (BIEL sounds confident that the Recovery RX ES will not face any significant regulatory hurdles)
Sales
The Dr Berend, Chief medical Officer of Ortho Alliance, presentation at the Musculoskeletal Care Symposium was based on all branches of the Ortho Alliance adopting use of the RecoveryRx (OrthoAlliance currently has 180+ physicians and more than 2,000 employees. Its partners now include 12 practices across Ohio, Kentucky, and Indiana)
Several Domestic and International distributor negotiations are in progress, the range from the final approval and registration stage to the initial exploration stage
(those in those in the 'final approval and registration' stage could happen any time now)
Legal Action
Mundipharma violated a 5 year contract to order a minimum of $14 million in BIEL devices, legal representation has been engaged in the US and Singapore to look into a lawsuit for this breach of contract (we know what happened to Mundipharma, caught up in the Sackler opioid lawsuits, but this does not absolve them of contractual obligations)
Only 300k shares sold at .0001 today, 124 million shares in Buys at 2 and 3
12.5 million shares traded at 2 after the market was closed.
MMs Shorted 62 million shares today.
Date ... Symbol .. Short vol ... Total vol
20240214 | BIEL | 62166622 || 138545854
Why tell the truth when made up numbers are so much better at promoting the basher/flipper agenda
<<<<<<<<<< Does it really matter? >>>>>>>>>>>
Yes, the truth matters. BS will get called out on the BIEL Board.
If someone wants to make a point about a Quarter with low Sales go for it. Just don't quote the Sales number as half of what it actually was because it will have more of an impact on the reader. That is BS with the intent of deceiving BIEL shareholders.
There seems to be a bad case of "misremembering" going around the basher club, it must be very contagious.
Also, interesting that you went back to Q3 of 2022 when there is a more recent Q1 2023 Sales figure, $158,077, available.
Must be getting your Sales data from Fantasy Sales Track
<<<<<<<<<<< only achieves sales of $25,000 >>>>>>>>>>>>
The ddls disclaimer says it all, he does not deal in facts, only opinions.
"Everything I say and write is my opinion and my opinion only"
Interesting that STADA went with Air Freight to move their ActiPatch shipment from Maryland to Saudi Arabia
They spent thousands of dollars more than using a container ship to have expedited access to their ActiPatch devices.
Qatar Airways tracking #157-96715636
https://www.qrcargo.com/s/track-your-shipment
There are some unknowns that would be needed to get a close estimate Miami
* was the retail box the larger, heavier 'Book Box' or the small 5"x5"x1" box
* weight of the pallets BIEL used
* weight of the large master packing boxes
* weight of the case quantity boxes
The good news is we know that this shipment arrived in Jeddah Saudi Arabia on 2/5/2024 so distribution to retailers in Saudi Arabia and Bahrain could already be in process.
When Dr Staelin announced the new STADA ActiPatch distributorship he also announced two other new orders, Modern Development Medical and Multiple Health Pharma, Ltd , " These two new international orders and the renewal order total in excess of $200,000.00." . Of these 3 BIEL partners STADA is the largest company by far so I would say that they had a significant portion of that $200k.
Looks like STADA already has BIEL's shipment, 1289 Pounds of ActiPatch Devices
157-96715636 (IAD - JED)
5 Piece(s) | 585 Kg | 6.597 m3
Delivered
Delivered in JED
5 Pcs | 585 Kg
Tue, 6 Feb 2024
12:00
Notified consignee
5 Pcs | 585 Kg
Mon, 5 Feb 2024
21:50
Received in JED
5 Pcs | 585 Kg
Mon, 5 Feb 2024
21:45
Arrived in JED on QR1186/05-Feb-2024
5 Pcs | 585 Kg | 6.61 m3
Mon, 5 Feb 2024
18:01
Departed on QR1186/05-Feb-2024 from DOH
5 Pcs | 585 Kg | 6.61 m3
Mon, 5 Feb 2024
15:14
Received in DOH
5 Pcs | 585 Kg | 6.61 m3
Sun, 4 Feb 2024
17:12
Arrived in DOH on QR0708/04-Feb-2024
5 Pcs | 585 Kg | 6.61 m3
Sun, 4 Feb 2024
15:37
Departed on QR0708/03-Feb-2024 from IAD
5 Pcs | 585 Kg | 6.61 m3
Sat, 3 Feb 2024
19:50
Received from shipper in IAD
5 Pcs | 585 Kg
Fri, 2 Feb 2024
12:14
He is a chronic complainer, BIEL could land a deal with Pfizer and he would find a problem with it.
Thanks YK, another BIEL distribution partner confirmed, STADA in MENA
Preceded by the 4/2023 Launch of ActiPatch in South Africa by Adcock Ingram.
Thanks toohot, Dr Berend is a heavy hitter in the Orthopedic World
Dr. Keith Berend
Joined JIS in 2013
Dr. Berend is a native of Columbus, Ohio. He is a member of the Knee Society and the Hip Society, the highest honor bestowed upon a surgeon with those respective specialties. Along with Dr. Lombardi, he is the only other surgeon in both societies in all of Ohio.
Dr. Berend is the author of over 250 scholarly articles and has presented his work and taught surgery around the globe.
He also serves as Chief Medical Development Officer for OrthoAlliance.
Education
B.S., Florida Southern College, Lakeland, FL
M.D., Duke University, Durham, NC
Residency
Orthopedic Residency, Duke University, Durham, NC
Fellowship
Adult Reconstruction of the Knee & Hip, Joint Implant Surgeons Inc., New Albany, OH
Honors
Florida Southern College Distinguished Alumni Award 2012
Leaders in Total Joint Replacement: Generation Next 2013
Top 22 Knee Surgeons in North America 2014 and 2015
Arthritis Foundation Pioneer in Medicine 2015
Champions of Health Care Award 2016
Jeanne and John G. McCoy Community Service Award 2016
Medical Mutual and Smart Business Pillar Community Service Award 2019
Columbus Monthly Top Doctors 2004-2023
I am sure 'Mr Sales Track' would love it if no one called out false posts
Sorry, ddls=prn331=challengemyknowledge=Terry, bashers are not getting Carte Blanche on the BIEL Board.
Wrong Again, continuing the streak of misinformation
<<<<<<<< Wasn't it RICH (Staelin) who proclaimed the SYNERGY deal >>>>>>>>>
Keith Nalepka hosted the 8/25/2022 conference call that announced the Synergy deal.
This event also gave the following information:
* BIEL has a working prototype for a rechargeable device, will need a new 510k
* BIEL's Goal is no further dilution
* OEM remains BIEL's main business model
* Adcock Ingram and Stada have not begun sales yet
* Don Joy will now operate under the Enovis name
* KT Tape is getting a new CEO
* BIEL's OEMs are reporting good efficacy
* BIEL is currently operating with 7 employees
* UCSD Dr. Illfeld Phantom Limb Trial is showing significant pain relief in 2 out of every 3 patients
* RecoveryRx ES under development with an oblong antenna shape, not sure if it will need a new 510k
You are on quite the downward spiral today
<<<<<<<<<< not enough money to pay their interest due them >>>>>>>>>>>>>
The interest on BIEL's convertible loans has always been added on to the loan balance it has never been paid on a Quarterly or Yearly basis. If you actually read those Financials that you complain about so much you would have seen the "Interest Accrued" column and know that fact.
The 3 years of IBEX and St Johns forgoing interest has saved BIEL $2.25 million.
Good Grief, How is the 12/22/2023 Chairman's Letter not "Communication with Stockholders"?
<<<<<<<<<<<< They have stopped all communication with stockholders >>>>>>>>>>>>>
End of Year Message From the Chairman of the Board of BioElectronics
BIEL | December 22, 2023
FREDERICK, MD, Dec. 22, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioElectronics Corp. (OTC: BIEL) is pleased to provide this end of year message to investors, customers, suppliers and other partners. As described below, the last six months have produced mixed results.
Research Update
We have seen good progress on the research side. An investigator-sponsored study at University of California San Diego (UCSD) for phantom limb was completed this last fall and the paper is now under peer review for publication. All indications are that the results are very positive, but they are embargoed until they appear in press. The quality of life study for dogs diagnosed with osteoarthritis has been tentatively accepted and is now being prepared for final publication in Veterinary Medicine and Science. The results of this double-blind, placebo-controlled study show that the treated dogs showed significant improvement in functionality and mobility after 14 days of treatment above and beyond the current prescription medicines being taken. If this paper is published, we plan to start actively marketing our RecoveryRx line into the veterinary market.
Two other clinical studies are now in the field. Stanford University is conducting a study on thumb arthritics and a second study at UCSD for post-surgical analgesia is expected to finish in June 2024.
Finally, we completed a new design for our RecoveryRx product that is better suited for surgery incisions and is 50% more powerful than the current version. We have already manufactured a limited supply of these units and are planning to apply for an expedited 510(k) from the FDA in the near future.
Distribution Update
News on the sales front is more mixed. We brought in two new distributors for Bulgaria and the Netherlands and will relaunch in Australia in early 2024. However, talks with a major distributor in Asia and the CIS countries fell through after about six months of conversation. KT Tape had a change in management and decided not to actively market our medical device. As a result, we revoked its exclusive distributor contract and are now looking for a new distributor.
Social Media Campaign
We launched a limited social media campaign to generate some sales and interest in our OTC product within the very lucrative US market. These direct to consumer (DTR) sales continue to result in strong consumer reviews. Aggregating the numerous product reviews (well over 1000) over the platforms selling our product shows that the vast majority (70% or more) of users give our product a 4 or 5 star rating. This figure is very similar to our published research findings that show about 66% of chronic pain sufferers find clinically significant relief within the first 7 days of use of our OTC product. Such findings have led to significant conversations with three major distributors who are in the pain space. However, to date, none of these conversations have resulted in a licensing or distribution agreement.
Need for Short-Term Financing
The lack of significant sales volume has severely limited the Company’s ability to actively market its product line. Most of the funding has come from inside investors (mainly myself). As has been the case for a number of years, the lack of positive cash flow has forced the Company to make many short-term decisions that have acted as a barrier for potential growth. It has also led to the Company looking for additional financing. The Company cannot provide assurances that it will be able to obtain the needed financing, on acceptable terms or otherwise. If the Company is unable to obtain short term financing, it is likely that the Company will need to explore strategic alternatives, including possible dissolution. In the event the Company does obtain financing, there can be no assurances the Company will be able to achieve any of the objectives or milestones described above.
On a more positive note, BioElectronics would like to extend Season Greetings to all its customers and loyal shareholders. Here’s to everyone’s health and prosperity.
Richard Staelin
Chairman of the Board
This is a CGM patch, Continuous Glucose Monitor, the adhesion mechanism is KT tape.
Your BFF Jimmy got a 50% discount on his 600 million share conversion
<<<<<<<<<< the family gets their conversion price at 50% discount >>>>>>>>>>>
No one on this Board, except for you apparently, believes that there is currently a market for 20+ billion new shares of BIEL.
<<<<< How is that good for the stockholders for when they do 'unload' their substantial amount of shares >>>>>
The only way KW, PW, and RS get their loans repaid is if BIEL becomes successful.
Since BIEL pays most of its debts in shares, a solvent BIEL trading at .002 lowers the convertible debt by a factor of 10, if it was 20 billion shares at a .0002 SP it is 2 billion shares at a .002 SP .
A successful BIEL trading at .02 lowers the convertible debt by a factor of 100, if it was 20 billion shares at a .0002 SP it is 200 million shares at a .02 SP .
The Whelans have the rights to billions of shares due to the convertible debt that they hold
The do not have possession of the shares until they convert the loans and thus can not currently "unload" them.
Wait a minute, if shareholders were dumping shares today why did the MMs need to Short 188 million shares?
Enough to cover all of today's 179 million shares in Selling with 9 million in change.
FINRA Daily Reg SHO Shorting Report
Date ... Symbol .. Short vol .... Total vol
20240206 | BIEL | 188288531 || 305766600
I am far from an expert on electromagnetic issues but someone who is explained it to me in an example most will understand
If I have a flashlight with 2,000 lumens that is the most light it is capable of producing. If that flashlight has a 'Focus Lense' I can use it as a 'Flood Light' to spread its 2,000 lumens over a wide area or I can use it as a 'Spot Light' to condense those 2,000 lumens into a narrow beam.
Reducing the ActiPatch antenna diameter size focuses its energy on a smaller area similar to the 'Spot Light' setting on a flashlight.
As for the rectangular shaped antenna on the new ActiPatch Surgical Incision device it may be covering a smaller square cm area but the big plus I see is placing the antenna wire very close on both sides of the incision. If you have ever had a large bruise and used an ActiPatch on it the area right under the antenna wire heals the quickest, returning to your normal skin color while the rest of the bruise is still discolored. That is because it receives the strongest signal.
For the nerds I got an opinion from AI but ihub could not handle the equations;
Question - A wearable PEMF device has a 12cm antenna, sending a 27.12 MHz signal, pulse frequency of 1000 Hz and a pulse width of 100 microseconds, and peak spatial power density of 73 microWatts/cm2, does the power within the treatment area increase if the antenna is reduced in size to 6cm?
Answer - To determine if the power within the treatment area increases when the antenna size is reduced from 12cm to 6cm, we need to understand how changing the antenna size affects the power density.
Given:
Frequency (f): 27.12 MHz
Pulse frequency: 1000 Hz
Pulse width: 100 microseconds
Peak spatial power density with the 12cm antenna: 73 microWatts/cm²
To analyze the effect of antenna size on power density:
Calculate the power radiated by the 12cm antenna using the given parameters.
Calculate the power radiated by the 6cm antenna using the same parameters.
Compare the power densities of both antennas.
The peak spatial power density (S) can be calculated using the formula:
Where:
?
P is the power radiated by the antenna.
?
A is the area over which the power is distributed.
For both antennas, the pulse width and pulse frequency are the same. Therefore, the power radiated by the antennas is the same.
The only difference between the two antennas is the area over which the power is distributed.
For the 12cm antenna:
113.1 cm2
For the 6cm antenna:
28.3 cm2
P is constant for both antennas, the power density is inversely proportional to the area. Therefore, the power density increases as the area decreases.
So, when the antenna size is reduced from 12cm to 6cm, the power density within the treatment area increases.
Yep toohot, anyone who has followed BIEL for several years knows it is a news driven stock
In June of 2016 BIEL started a 7 month slide from .0016 to .0003 at the end of the year. Early in 2017 BIEL had 4 Weekly Lows of .0002 .
On February 6, 2017 BIEL announced FDA Clearance for Plantar Fasciitis and Osteoarthritis of the Knee. Over the next 2 weeks BIEL shot up to a High of .003 with over 4.3 billion shares traded.
In the original design ActiPatch and RecoveryRx have the same specs except that RecoveryRx offered options on the antenna diameter size.
<<<<<<<<<< the difference in performance between the Actipatch & Recovery RX >>>>>>>>>>>
Having two separate names allowed different marketing strategies for Retail and Medical Professional use.
BIEL is claiming a 50% power increase for the new Surgical Incision RecoveryRx which would give it a definite advantage over the ActiPatch for healing after surgery. It is likely this power increase was achieved by focusing the device's power, by use of an elongated rectangular shaped antenna, directly on the surgical incision. This method of increasing the power, with an unchanged power supply, should result in a simpler FDA Clearance.
Spoken Like a True Flipper
Is it really that hard to understand?
Dr. Staelin and the BIEL Team has gone from Quarterly Reporting to one Financial Report each Year to conserve financial resources and stay in business. This saves thousands of dollars each quarter in accounting expenses.
I know some of you would rather see BIEL throw in the towel but they are still in business and looking for opportunities to turn the company around.
Once again a lack of understanding the situation
The Boots years gave BIEL its largest revenue years, 2015, 2016, 2017 . It also gave BIEL some of its largest Net Losses because of the costs for a small, one product company to operate in the UK retail space. BIEL exited Boots in 2018 because they were losing money, due to the high costs not because of poor sales, and the NHS approval looked like a way of cutting costs. The NHS proved to be a bust because being on the NHS Drug Tariff does not guarantee that each local NHS bureaucracy, who have had their budgets cut for decades, would authorize paying for all Drug Tariff products. This was an error on BIEL's part for not doing enough research on the NHS system.
KT, with multiple products at Boots, gets volume discounts on their Boots shelf space so they have a much better chance of success there.
Switching to 720 hour Wave Sale
It was KT's decision to launch with a 250 hour Wave that was priced higher, than the 720 hour ActiPatch, bad decision.
The 720 hour Wave is now available in the UK and Ireland at Boots stores. Hopefully it will make it to the US.
Makes no sense to use an antenna designed for use on surgery incisions, long rectangular shape, on Thumb Arthritis
The logical choice for Thumb use would be the 6 cm diameter antenna, which would focus the device energy on 30 square cm rather than the 110 square cm that the standard 12 cm diameter antenna would cover.